| Literature DB >> 34150390 |
Dzemail Detanac1, Mehmed Mujdragic1, Dzenana A Detanac2, Enes Zogic1, Lejla Ceranic3, Kemal Alihodzic1, Mersudin Mulic4, Hana Mujdragic5.
Abstract
Introduction Necrotizing fasciitis is a severe inflammatory disease of the body's soft tissue characterized by spreading rapidly and high mortality. Rapid surgical intervention along with other supportive measures of treatment have a great impact on the outcome of treatment. Material and methods This study was conducted by a retrospective medical record review of all patients with a microbiologically and clinically confirmed diagnosis of necrotizing fasciitis who were admitted to the general surgery department at the General Hospital Novi Pazar, Serbia, during the period between 2017 and 2020. Demographic, clinical, laboratory, and microbiology data were analyzed. Results A total of 13 cases were identified, which represents 0.21% of the total number of patients treated at the surgical department during the period January 2017 to November 2020. The mean age of patients was 55 years, with a male/female ratio of 1:1.6. All of them had at least one comorbidity and more than half had three or more. Diabetes, cardiovascular diseases, and obesity were the most common comorbidities. The most common causes of infection were Klebsiella spp, Pseudomonas aeruginosa, S. pyogenes, and S. aureus. All patients received multiple surgical interventions (mean 2.3). Conclusion Treating necrotizing fasciitis requires a multidisciplinary approach. Early diagnosis and rapid clinical response allow for better disease outcomes. Getting to know more about necrotizing fasciitis will help doctors make better decisions when treating it.Entities:
Keywords: fasciitis; general surgery; necrotizing fasciitis; soft tissue infection
Year: 2021 PMID: 34150390 PMCID: PMC8202215 DOI: 10.7759/cureus.15039
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Patients' comorbidities
DM: diabetes mellitus; HBP: high blood pressure; CKD: chronic renal disease; HCV: hepatitis C virus
| Patients | DM | HBP | CKD | HCV | Obesity | Heart disease | Malignancy |
| 1. | + | + | + | + | + | ||
| 2. | + | + | + | ||||
| 3. | + | + | + | ||||
| 4. | + | + | + | ||||
| 5. | + | + | + | + | + | ||
| 6. | + | + | |||||
| 7. | + | ||||||
| 8. | + | + | + | + | + | + | |
| 9. | + | + | |||||
| 10. | + | + | + | + | |||
| 11. | + | + | + | ||||
| 12. | + | ||||||
| 13. | + |
Initial infected site, surgical debridement region, and number of surgical debridement
| Initial infected site | Surgical debridement region | Number of surgical debridements | |
| 1. | Vulvar regions | anterior abdominal wall, perineum, inguinal region | 4 |
| 2. | Umbilical hernia operation | anterior abdominal wall | 6 |
| 3. | Perianal fistula | perineum and scrotum, as well as to both gluteal regions of the perianal region | 3 |
| 4. | Right groin | right femoral and pubic region, infraumbilically bilateral anterior abdominal wall, pubic and right gluteal region | 2 |
| 5. | The site of the operative incision after uterine tumor surgery | anterior abdominal wall | 2 |
| 6. | Right femoral region | right femoral and inguinal region and perineum | 1 |
| 7 | Upper arm after IV drug use | left arm and anterior wall of left hemithorax | 2 |
| 8 | The site of the operative incision after uterine tumor surgery | anterior abdominal wall | 2 |
| 9 | Trauma | left thigh ( lateral and posterior region) | 1 |
| 10 | Perianal abscess | perineum, gluteal, and perianal region | 2 |
| 11 | Unknown | anterior abdominal wall, perineum, both inguinal region, scrotum, both femoral region | 2 |
| 12 | Surgical intervention | lower leg | 1 |
| 13 | Perianal abscess | perianal and gluteal region, perineum | 2 |
Figure 1Patient with infected perineum and scrotum
Figure 2A: Intraoperative finding for patient No. 11: debridement of the left and right groin extending to the left thigh and scrotum
Figure 3B: Intraoperative finding for patient No. 11: debridement of the left and right groin extending to the left thigh and scrotum
Initially laboratory findings and LRINEC score at admission
WBC: white blood cells; RBC: red blood cells; BMI: body mass index; HGB: hemoglobin; LRINEC: Laboratory Risk Indicator for Necrotizing Fasciitis
| Patients | M/F | Year | CRP | WBC | RBC | HGB | Glycemia | Creatinine | BMI | Na+ | LRINEC |
| 1. | F | 53 | 308.7 | 36.3 | 5.02 | 152 | 5.2 | 76 | 31.8 | 136 | 6 |
| 2 | F | 59 | 296.5 | 39.2 | 4.07 | 134 | 25.4 | 88 | 40.2 | 139 | 8 |
| 3 | M | 54 | 403.7 | 26 | 4.08 | 121 | 41 | 222 | 37.5 | 135 | 11 |
| 4 | F | 64 | 350 | 27 | 4.34 | 129 | 32 | 158 | 26.7 | 135 | 10 |
| 5 | F | 60 | 253 | 21.4 | 3.56 | 112 | 16 | 148 | 35.8 | 136 | 7 |
| 6 | F | 40 | 498.6 | 33.5 | 4.62 | 122 | 25 | 120 | 51.9 | 137 | 8 |
| 7 | M | 27 | 289.6 | 21.5 | 3.24 | 113 | 9 | 98 | 20.1 | 141 | 6 |
| 8 | F | 73 | 367 | 28.3 | 3.01 | 101 | 19 | 121 | 34.5 | 139 | 9 |
| 9 | M | 59 | 271 | 19 | 5.09 | 145 | 16 | 91 | 30.9 | 140 | 5 |
| 10 | F | 54 | 221 | 23 | 4.43 | 131 | 19 | 167 | 32.1 | 136 | 9 |
| 11 | M | 61 | 351 | 32.7 | 2.95 | 101 | 39 | 189 | 27.2 | 134 | 12 |
| 12 | M | 64 | 169 | 21 | 3.88 | 121 | 15 | 100 | 26.1 | 139 | 5 |
| 13 | F | 54 | 201 | 19 | 4.76 | 127 | 18 | 99 | 27.7 | 136 | 6 |